v3.22.2.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jul. 31, 2022
Oct. 31, 2021
Current assets:    
Cash and cash equivalents $ 24,254 $ 29,128
Short-term investments 7,410 6,599
Prepaid expenses and other current assets 676 276
Total current assets 32,340 36,003
Operating lease right-of-use asset 223 254
Total assets 32,563 36,257
Current liabilities:    
Accounts payable 227 136
Accrued expenses 1,198 1,095
Operating lease liability 44 39
Total current liabilities 1,469 1,270
Operating lease liability, non-current 187 220
Total liabilities 1,656 1,490
Commitments and contingencies (Note 9)  
Shareholders’ equity:    
Preferred stock
Common stock, par value $.01 per share; 100,000,000 shares authorized; 30,653,418 and 30,050,894 shares issued and outstanding as of July 31, 2022 and October 31, 2021, respectively 307 301
Additional paid-in capital 246,303 239,927
Accumulated deficit (214,909) (204,790)
Total shareholders’ equity 31,701 35,438
Noncontrolling interest (Note 1) (794) (671)
Total equity 30,907 34,767
Total liabilities and equity 32,563 36,257
Series A Convertible Preferred Stock [Member]    
Shareholders’ equity:    
Preferred stock

Source

v3.22.2.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Jul. 31, 2022
Jul. 31, 2021
Jul. 31, 2022
Jul. 31, 2021
Income Statement [Abstract]        
Revenue $ 513
Operating costs and expenses:        
Inventor royalties, contingent legal fees, litigation and licensing expenses 385
Research and development expenses (including non-cash share-based compensation expenses of $771, $1,688, $3,014 and $2,425, respectively) 1,445 2,167 5,018 4,017
General and administrative expenses (including non-cash share-based compensation expenses of $667, $1,500, $2,460 and $2,800, respectively) 1,352 2,221 5,248 5,170
Total operating costs and expenses 2,797 4,388 10,266 9,572
Loss from operations (2,797) (4,388) (10,266) (9,059)
Interest income 22 24 2
Net loss (2,775) (4,388) (10,242) (9,057)
Less: Net loss attributable to noncontrolling interest (29) (54) (123) (116)
Net loss attributable to common shareholders $ (2,746) $ (4,334) $ (10,119) $ (8,941)
Net loss per common share attributable to common shareholders:        
Basic and diluted $ (0.09) $ (0.14) $ (0.33) $ (0.32)
Weighted average common shares outstanding:        
Basic and diluted 30,451 30,455 30,244 28,090

Source

v3.22.2.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
9 Months Ended
Jul. 31, 2022
Jul. 31, 2021
Reconciliation of net loss to net cash used in operating activities:    
Net loss $ (10,242) $ (9,057)
Stock option compensation to employees and directors 4,928 4,804
Stock options and warrants issued to consultants 546 421
Common stock issued to consultants 72
Gain on sale of equipment (5)
Amortization of operating lease right-of-use asset 31 44
Change in operating assets and liabilities:    
Prepaid expenses and other current assets (400) (119)
Accounts payable 91 (25)
Accrued expenses 103 89
Operating lease liability (28) (45)
Net cash used in operating activities (4,899) (3,893)
Cash flows from investing activities:    
Disbursements to acquire short-term investments (11,159) (10,399)
Proceeds from maturities of short-term investments 10,348 3,640
Proceeds from sale of equipment 35
Net cash used in investing activities (811) (6,724)
Cash flows from financing activities:    
Gross proceeds from sale of common stock in a public offering 22,500
Expenses of the public offering (2,208)
Gross proceeds from sale of common stock in an at-the-market offering 11,175
Expenses of the at-the-market offering (341)
Proceeds from sale of common stock pursuant to employee stock purchase plan 6 3
Proceeds from exercise of stock options 830 293
Net cash provided by financing activities 836 31,422
Net (decrease) increase in cash and cash equivalents (4,874) 20,805
Cash and cash equivalents at beginning of period 29,128 6,417
Cash and cash equivalents at end of period $ 24,254 $ 27,222

Source